Purification and characterization of a new recombinant factor VIII (N8).
about
P1343
Lipid nanotechnologies for structural studies of membrane-associated proteinsA new recombinant factor VIII: from genetics to clinical use.Expression and characterization of a codon-optimized blood coagulation factor VIII.A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat.Helical organization of blood coagulation factor VIII on lipid nanotubes.A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.Sequencing the CHO DXB11 genome reveals regional variations in genomic stability and haploidy.Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based systemCircumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogsMissense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.Advances in the treatment of inherited coagulation disorders.Investigational drugs for coagulation disorders.Blood Clotting Factor VIII: From Evolution to Therapy.Innovative approach for improved rFVIII concentrate.Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.Turoctocog alfa for the treatment of hemophilia a.The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia AUpdates from guardian™: a comprehensive registration programme.Emerging drugs for the treatment of hemophilia A and B.Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats.Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules.Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule.Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion proteinFactor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa.International comparative field study of N8 evaluating factor VIII assay performance.Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGE.Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.
P2860
Q30363926-BC839968-12BB-4743-9FF4-BD5A5A6EE7A5Q30370282-105AE46C-65E0-4886-A87E-66FED6EE998DQ30397756-D815A70D-109C-4F22-832C-66ED24E73A03Q30426130-162A8EC5-80FC-4B92-AD4A-05ABC1550222Q33552218-5A6FD5B1-BC05-4278-89E4-18008A791A1FQ34018596-92F6D41B-5C5E-4207-BF92-64CD7A9087E8Q34557556-CA717F0F-9416-42A0-854C-117741DDFAE5Q35023255-6CB5F7C4-189E-4B5D-A801-BE47DEDA741FQ35174495-35E048C0-6A1C-4909-8A58-33228D72860EQ35607209-AA40D7C7-5A76-48FF-9F7E-407655DEDF49Q35611898-9C3D713B-AADC-4367-8A53-6E7BF09C464DQ36322576-B7B017CC-E016-4BC3-A422-FEDF9381B05EQ37316242-678B0EC5-343E-4051-8CE3-529C2DEC2EA7Q37585275-AEB757BB-B34B-4B5C-A670-B4170AD71D3BQ37591484-B4E5BE5D-89D6-4652-872A-5AD3F8639AE4Q37715039-A9600F9C-12DC-4113-A598-FCBF59E833E0Q38100271-69B41690-7C47-480C-9331-3E2517A5A6CFQ38106245-53111AD1-126A-4938-A460-32C0342A1FE9Q38118763-48F64DBD-C87B-43BD-AD32-82A80A52B0F0Q38207134-213E8CAB-045A-4C1D-82DF-9465574DA5BAQ38209486-23D1895F-7DF0-407A-B12C-32A15DAE59FAQ38232780-620EE4B2-7D4E-4F8E-A6FE-A9D9F8CAFC69Q38286285-85EF96FA-8260-4E1E-9CCF-1EE1C5AD2959Q38408739-CF450EF1-1213-4903-8B0B-E125CEE7E6E4Q38672491-67F198C7-5088-4362-A1F6-D2C014070527Q38933707-1BF8E1A0-8D01-4777-AED9-72D1CAD00D66Q39204747-87BBAD2F-22B3-4CDD-A895-E4A9A1ABFD66Q39631688-8422E938-BA5D-4A6C-9BA4-BCF3A277B347Q39952594-B2A9ABB0-DE01-4EFD-B643-57977D9D1BD0Q40113613-299891A0-B4C0-4398-BA6D-754DEFBF06F6Q40159945-76AD0EC5-C82D-43E2-ACAB-B027F3221A58Q40573329-7C4C90D5-B100-4066-AAB8-FAD0782754D5Q41611929-CE3DC813-9F5C-4B11-A037-0759491C0434Q41966328-41AD70D6-156C-402A-BF03-4F24B35A01F1Q43088590-B86E54BE-5A9C-4A26-9170-2D7F2F2CF017Q45868601-1AECB0F4-C6B1-4729-B5F4-EB1C94421CACQ45868800-6109ECD7-08F7-413B-A52F-76967AED7885Q45869545-6CBE64E9-A5EB-4FB1-94D6-A4A1BCA22BB4Q45871898-AD0C51BD-FBC9-430F-8368-4627A1CA5E4CQ45872547-4C0B3560-C553-4EB6-B810-F91D6D93E442
P2860
Purification and characterization of a new recombinant factor VIII (N8).
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Purification and characterization of a new recombinant factor VIII (N8).
@ast
Purification and characterization of a new recombinant factor VIII (N8).
@en
type
label
Purification and characterization of a new recombinant factor VIII (N8).
@ast
Purification and characterization of a new recombinant factor VIII (N8).
@en
prefLabel
Purification and characterization of a new recombinant factor VIII (N8).
@ast
Purification and characterization of a new recombinant factor VIII (N8).
@en
P2093
P2860
P1433
P1476
Purification and characterization of a new recombinant factor VIII (N8).
@en
P2093
J Karlsson
J M Petersen
J Pedersen
L B Johnsen
N K Klausen
P2860
P304
P356
10.1111/J.1365-2516.2009.02135.X
P4510
P577
2009-11-11T00:00:00Z